Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH

GlobeNewsWire • Dec 11, 2025

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 39,575 shares of its common stock and granted an aggregate of 26,525 restricted stock unit (“RSU”) awards to 9 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Dec 10, 2025

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors and other SST2-expressing solid tumors. CRN09682 is the lead candidate from Crinetics' proprietary nonpeptide drug conjugate (NDC) platform, which leverages the company's expertise in GPCR drug discovery and small molecule design to develop a pipeline of modular targeted therapies for endocrine and endocrine-related tumors.

GlobeNewsWire • Dec 3, 2025

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year

Boston-based MPM BioImpact sold 428,975 shares of Crinetics Pharmaceuticals worth about $12.3 million in the third quarter. The move marked a full exit for MPM, which reported holding no shares of CRNX at quarter-end.

The Motley Fool • Nov 27, 2025

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

CAREFNDR underscores the potential clinical value of p altusotine b eyond acromegaly, and demonstrates progress in Crinetics' commitment to addressing unmet needs in the neuroendocrine tumor community  SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX) today announced the first patient has been randomized in the pivotal Phase 3 CAREFNDR trial, a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of once-daily, oral paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors.

GlobeNewsWire • Nov 20, 2025

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,675 shares of its common stock and granted an aggregate of 25,300 restricted stock unit (“RSU”) awards to 11 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Nov 10, 2025

Why Crinetics Pharmaceuticals Stock Was Sliding on Friday

The biotech unveiled its third-quarter results. They didn't meet analyst expectations, but there was good news in the update.

The Motley Fool • Nov 7, 2025

Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. ( CRNX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Gayathri Diwakar - Senior Director of Investor Relations R. Struthers - Founder, President, CEO & Director Isabel Kalofonos - Chief Commercial Officer Tobin Schilke - Chief Financial Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Cory Jubinville - LifeSci Capital, LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Douglas Tsao - H.C.

Seeking Alpha • Nov 7, 2025

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

PALSONIFY™ (Paltusotine) Launched in the U.S. with Encouraging Early Feedback from Patients and Physicians, and Positive Reimbursement Trends       Reiterates Cash Burn of $340-370M and Cash Runway into 2029       Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the third quarter ended September 30, 2025.

GlobeNewsWire • Nov 6, 2025

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to a loss of $0.96 per share a year ago.

Zacks Investment Research • Nov 6, 2025